– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox –
– Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter 2021 –
– Conference Call at 8:30 a.m. ET Today –
DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2021 and provided an operational update.
“We made considerable progress throughout the first half of 2021, highlighted by the acquisition of Oncoceutics, the initiation of the Phase 3 DASH AML trial, and the FDA approval of TEMBEXA as a medical countermeasure for smallpox. This approval is an important milestone as it marks Chimerix’s first FDA approved drug and is the first smallpox antiviral approved for all age groups, including infants, with an available oral solution for patients who have difficulty swallowing,” said Mike Sherman, Chief Executive Officer of Chimerix. “Looking ahead to the balance of the year, we expect to report the efficacy analysis by BICR for ONC201 and complete TEMBEXA manufacturing to support U.S. national preparedness.”
Recent Highlights
TEMBEXA for Smallpox
In June, the FDA granted TEMBEXA tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients and is the first and only smallpox therapy approved for neonates. The oral suspension formulation is particularly important for patients who have difficulty swallowing due to age or medical status.
TEMBEXA potentially fills an important role as a treatment countermeasure to smallpox; it has a differentiated mechanism of action, a relatively high barrier to resistance and available evidence suggests it can be used in patients who have received the other approved smallpox antiviral treatment. By year-end, Chimerix expects to complete initial TEMBEXA drug product manufacturing in order to satisfy a potential procurement contract to support national preparedness in the United States.
Imipridones and ONC201
Chimerix’s acquisition of Oncoceutics, Inc., expands the Company’s oncology franchise with a late-stage, novel class of small molecule anti-cancer compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce tumor cell death in multiple cancer types.
The BICR of radiographic imaging will enable clinical efficacy analyses of the first 50 patients with recurrent H3-K27M-mutant diffuse midline glioma who received single agent ONC201. These analyses will include overall response rate and key supportive endpoints, such as durability of response and other measures of clinical benefit. If favorable, these data may form the basis for an NDA submission seeking accelerated approval of ONC201 in the United States.
In addition, a Phase 1 clinical trial for ONC206, our second imipridone product candidate, and IND-enabling work for our third imipridone candidate, ONC212, remain ongoing.
DSTAT for AML
Chimerix continues enrollment in the Phase 3 Dociparstat in AML with Standard Chemotherapy (DASH AML) study of DSTAT for the treatment of AML. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of DSTAT in combination with standard intensive induction and consolidation chemotherapy for the treatment of newly-diagnosed AML patients. Chimerix expects to unblind data following enrollment of the first 80 evaluable patients in this study to assess complete response rates and minimal residual disease rates between the study arm and the control arm. This analysis is expected to take place in the second half of 2022.
Expected 2021 Milestones
- Negotiation of a smallpox procurement agreement for TEMBEXA
- Completion of TEMBEXA drug product manufacturing to support potential shipments up to $100 million for U.S. national preparedness
- Efficacy analysis by blinded independent central review of 50-subject registration cohort of ONC201 in recurrent H3 K27M-mutant glioma
Second Quarter 2021 Financial Results
Chimerix reported a net loss of $17.8 million, or $0.21 per basic and diluted share, for the second quarter of 2021. During the same period in 2020, Chimerix recorded a net loss of $10.0 million, or $0.16 per basic and diluted share.
Revenues for the second quarter of 2021 decreased to $0.4 million, compared to $1.4 million for the same period in 2020.
Research and development expenses increased to $13.8 million for the second quarter of 2021, compared to $8.6 million for the same period in 2020.
General and administrative expenses increased to $4.4 million for the second quarter of 2021, compared to $3.1 million for the same period in 2020.
Chimerix's balance sheet at June 30, 2021, included approximately $140 million of capital available to fund operations, $14.0 million in a note payable related to the Oncoceutics transaction and approximately 86.2 million outstanding shares of common stock.
Conference Call and Webcast
Chimerix will host a conference call and live audio webcast to discuss second quarter 2021 financial results and provide a business update today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 6658827.
A live audio webcast of the call will also be available on the Investors section of Chimerix’s website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and an efficacy analysis by blinded independent central review is expected later in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.
About TEMBEXA
TEMBEXA is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates. TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease. The effectiveness of TEMBEXA for the treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. TEMBEXA efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals.
TEMBEXA (brincidofovir) is a nucleotide analog lipid-conjugate designed to mimic a natural monoacyl phospholipid to achieve effective intracellular concentrations of the active antiviral metabolite, cidofovir diphosphate. Cidofovir diphosphate exerts its orthopoxvirus antiviral effects by acting as an alternate substrate inhibitor for viral DNA synthesis mediated by viral DNA polymerase.
IMPORTANT SAFETY INFORMATION Including BOXED WARNING
| WARNING: INCREASED RISK FOR MORTALITY WHEN USED FOR LONGER DURATION An increased incidence of mortality was seen in TEMBEXA-treated subjects compared to placebo-treated subjects in a 24-week clinical trial when TEMBEXA was evaluated in another disease. |
WARNINGS AND PRECAUTIONS
Elevations in Hepatic Transaminases and Bilirubin: May cause increases in serum transaminases (ALT or AST) and serum bilirubin. Monitor liver laboratory parameters before and during treatment.
Diarrhea and Other Gastrointestinal Adverse Events: Diarrhea and additional gastrointestinal adverse events including nausea, vomiting, and abdominal pain may occur. Monitor patients, provide supportive care, and if necessary, do not give the second and final dose of TEMBEXA.
Coadministration with Related Products: TEMBEXA should not be co-administered with intravenous cidofovir.
Carcinogenicity: TEMBEXA is considered a potential human carcinogen. Do not crush or divide TEMBEXA tablets and avoid direct contact with broken or crushed tablets or oral suspension.
Male Infertility: Based on testicular toxicity in animal studies, TEMBEXA may irreversibly impair fertility in individuals of reproductive potential.
ADVERSE REACTIONS
Common adverse reactions (adverse events assessed as causally related by the investigator in ≥ 2% of subjects) experienced in the first 2 weeks of dosing with TEMBEXA were diarrhea, nausea, vomiting and abdominal pain.
USE IN SPECIFIC POPULATIONS
Pregnancy
Based on findings from animal reproduction studies, TEMBEXA may cause fetal harm when administered to pregnant individuals. Pregnancy testing should be performed before initiation of TEMBEXA in individuals of childbearing potential to inform risk. An alternative therapy should be used to treat smallpox during pregnancy, if feasible.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the status of Chimerix’s oncology programs, and the potential benefits and government procurement of TEMBEXA. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that the current clinical study data for ONC201 will not support accelerated, or any, regulatory approval; the anticipated benefits of the acquisition of Oncoceutics may not be realized; the ability to generate positive results in a Phase 3 study in acute myeloid leukemia and subsequent approval for DSTAT; risks that Chimerix will not obtain a procurement contract for TEMBEXA in smallpox in a timely manner or at all; Chimerix’s reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
| CHIMERIX, INC. | ||||||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||||||
| (in thousands, except share and per share data) | ||||||||||||
| (unaudited) | ||||||||||||
| June 30, | December 31, | |||||||||||
| 2021 | 2020 | |||||||||||
| ASSETS | ||||||||||||
| Current assets: | ||||||||||||
| Cash and cash equivalents | $ | 25,445 | $ | 46,989 | ||||||||
| Short-term investments, available-for-sale | 106,584 | 31,973 | ||||||||||
| Accounts receivable | 36 | 340 | ||||||||||
| Prepaid expenses and other current assets | 4,185 | 2,356 | ||||||||||
| Total current assets | 136,250 | 81,658 | ||||||||||
| Long-term investments | 7,535 | - | ||||||||||
| Property and equipment, net of accumulated depreciation | 298 | 214 | ||||||||||
| Operating lease right-of-use assets | 2,612 | 2,825 | ||||||||||
| Other long-term assets | 30 | 26 | ||||||||||
| Total assets | $ | 146,725 | $ | 84,723 | ||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||
| Current liabilities: | ||||||||||||
| Accounts payable | $ | 1,457 | $ | 1,283 | ||||||||
| Accrued liabilities | 9,465 | 7,250 | ||||||||||
| Note payable | 14,000 | - | ||||||||||
| Total current liabilities | 24,922 | 8,533 | ||||||||||
| Lease-related obligations | 2,654 | 2,814 | ||||||||||
| Total liabilities | 27,576 | 11,347 | ||||||||||
| Stockholders’ equity: | ||||||||||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized at June 30, 2021 and | ||||||||||||
| December 31, 2020; no shares issued and outstanding as of June 30, 2021 and | ||||||||||||
| December 31, 2020 | - | - | ||||||||||
| Common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2021 and | ||||||||||||
| December 31, 2020; 86,249,744 and 62,816,039 shares issued and outstanding as of | ||||||||||||
| June 30, 2021 and December 31, 2020, respectively | 86 | 63 | ||||||||||
| Additional paid-in capital | 946,612 | 785,673 | ||||||||||
| Accumulated other comprehensive loss, net | (11 | ) | - | |||||||||
| Accumulated deficit | (827,538 | ) | (712,360 | ) | ||||||||
| Total stockholders’ equity | 119,149 | 73,376 | ||||||||||
| Total liabilities and stockholders’ equity | $ | 146,725 | $ | 84,723 | ||||||||
| CHIMERIX, INC. | |||||||||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||
| Revenues: | |||||||||||||||||||||
| Contract revenue | $ | 390 | $ | 1,396 | $ | 1,823 | $ | 2,567 | |||||||||||||
| Licensing revenue | 1 | 6 | 3 | 76 | |||||||||||||||||
| Total revenues | 391 | 1,402 | 1,826 | 2,643 | |||||||||||||||||
| Operating expenses: | |||||||||||||||||||||
| Research and development | 13,798 | 8,578 | 25,660 | 17,527 | |||||||||||||||||
| General and administrative | 4,408 | 3,110 | 8,544 | 6,315 | |||||||||||||||||
| Acquired in-process research and dvelopment | - | - | 82,890 | - | |||||||||||||||||
| Total operating expenses | 18,206 | 11,688 | 117,094 | 23,842 | |||||||||||||||||
| Loss from operations | (17,815 | ) | (10,286 | ) | (115,268 | ) | (21,199 | ) | |||||||||||||
| Other income: | |||||||||||||||||||||
| Interest income and other, net | 52 | 270 | 90 | 763 | |||||||||||||||||
| Net loss | (17,763 | ) | (10,016 | ) | (115,178 | ) | (20,436 | ) | |||||||||||||
| Other comprehensive loss: | |||||||||||||||||||||
| Unrealized gain (loss) on debt investments, net | 32 | 141 | (11 | ) | 95 | ||||||||||||||||
| Comprehensive loss | $ | (17,731 | ) | $ | (9,875 | ) | $ | (115,189 | ) | $ | (20,341 | ) | |||||||||
| Per share information: | |||||||||||||||||||||
| Net loss, basic and diluted | $ | (0.21 | ) | $ | (0.16 | ) | $ | (1.38 | ) | $ | (0.33 | ) | |||||||||
| Weighted-average shares outstanding, basic and diluted | 86,255,836 | 62,042,778 | 83,231,600 | 61,892,407 | |||||||||||||||||